Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Elan, Royalty Pharma neurology news

Royalty said it raised its offer to acquire Elan for a third time, now valuing the biotech at up to $7.9 billion from $6.4 billion, based on 510.3 million shares outstanding at May 10. Elan said its board will assess the revised offer and advised shareholders take no action in the meantime. For each share held, Elan shareholders will receive $13 in cash and a contingent value right (CVR) worth up to $2.50 tied to a label expansion for Tysabri

Read the full 803 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE